Normal view MARC view ISBD view

Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?

O'Reilly, Eileen M

Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred? [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology 06 2020 - 1757-1759 p. digital

Publication Type: Editorial; Research Support, N.I.H., Extramural; Comment

ISSN: 1527-7755

Standard No.: 10.1200/JCO.19.03318 doi

Subjects--Topical Terms:
Chemoradiotherapy
Humans
Neoadjuvant Therapy
Pancreatic Neoplasms--drug therapy

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)